Alpha Cognition Announces First Patient Enrolled in RESOLVE Phase 4 Study Evaluating ZUNVEYL® in Patients with Mild to Moderate Alzheimer’s Disease
Go back to Alpha Cognition Announces First Patient Enrolled in RESOLVE Phase 4 Study Evaluating ZUNVEYL® in Patients with Mild to Moderate Alzheimer’s Disease| (NASDAQ: ACOG) | Delayed: 6.58 -0.18 (2.66%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $6.76 | 52 Week High | $ | |||
| Open | $6.72 | 52 Week Low | $ | |||
| Day High | $6.75 | P/E | N/A | |||
| Day Low | $6.45 | EPS | $ | |||
| Volume | 61,094 | |||||
